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Background: Postoperative nausea and vomiting (PONV) frequently develops in patients undergoing thyroidectomy, 
and propofol-based total intravenous anesthesia (TIVA) has been reported to reduce the incidence of PONV. 
The present study was undertaken to compare the effects of ramosetron on PONV in women following total 
thyroidectomy under TIVA. 
Methods: One hundred and thirty women scheduled for thyroidectomy were allocated to either a control group (n 
= 65) or a ramosetron group (n = 65). Propofol in combination with remifentanil was used for TIVA in all patients. 
2 ml of either intravenous saline (control group) or 0.3 mg of ramosetron (ramosetron group) were administered at 
the end of the surgery. Fentanyl-based patient-controlled analgesia was implemented for 48 h after surgery in all 
patients. The incidences and severities of PONV, pain scores, administrations of rescue antiemetics, and the side 
effects of the antiemetics were documented during the first 48 h after surgery. 
Results: The incidences of complete response (no PONV, no rescue) in the control and ramosetron groups were 71% 
and 88%, respectively, during the first 6 h (P = 0.029), 85% and 94% during the next 6 to 24 h period (P = 0.155), and 
97% and 95% during the last 24 to 48 h period (P = 1.00). During the first 6 h, the severity of nausea and the use of 
rescue antiemetic medication were significantly lower in the ramosetron group.
Conclusions: Ramosetron was found to be effective at reducing the incidence and severity of postoperative nausea 
in women that underwent total thyroidectomy with propofol-based TIVA, especially during the first 6 hours 
postoperatively.  (Korean J Anesthesiol 2011; 61: 154-158)
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Introduction
    Postoperative nausea and vomiting (PONV) is a distressing 
and common adverse effect in patients undergoing thyroidec-
tomy. The etiology of PONV after thyroidectomy is unknown, 
but is probably related to several factors, which include age, sex, 
and intense vagal stimulation related to the surgical handling of 
the neck [1]. Other factors, including obesity, a history of motion 
sickness and/or of previous postoperative emesis, anesthetic 
technique, and postoperative pain are also considered to 
increase the incidence of PONV [2]. When no prophylactic anti-
emetic is provided, the reported incidence of PONV varies from 
60% to 76% after thyroidectomy [3-5]. 
    The optimal strategy for preventing PONV remains con-
tentious. Global prophylaxis for PONV is generally not recom-
mended, although it has been demonstrated to be cost effective 
in high risk patients [6]. However, since propofol is known to 
have an antiemetic effect, propofol-based total intravenous 
anesthesia (TIVA) has been used to decrease PONV [7]. White 
et al. [8] suggested that since TIVA reduces the predicted rate 
of PONV during the early postoperative period, a long-acting 
antiemetic might be necessary to prevent post-discharge 
nausea and vomiting after day-case surgery.
    Ramosetron (Nasea
Ⓡ, Astellas, Tokyo) is an antagonist of the 
5-hydroxytryptamine type 3 (5-HT3) receptor and has been 
reported to effectively prevent PONV after various surgeries 
[4,5,9-12]. However, no data is available on the use of IV 
ramosetron as an antiemetic against PONV in patients receiving 
TIVA during thyroidectomy. The purpose of this study was to 
investigate the preventative effects of ramosetron on PONV in 
women after undergoing total thyroidectomy with propofol-
based TIVA. 
Materials and Methods
    After obtaining Institutional Review Board approval and 
patient consent, 130 female patients, aged 18 to 65, scheduled 
for total thyroidectomy were enrolled in this prospective study. 
Before anesthesia, patients with a risk of PONV exceeding 
60% were selected using a simplified risk scoring system 
devised by Apfel et al. [13]. The four risk factors considered 
were female gender, non-smoking, the use of postoperative 
opioids, and a prior history of motion sickness or PONV. 
According to this system, the presence of 0, 1, 2, 3, or 4 of 
these risk factors correspond to approximately 10, 20, 40, 60, 
and 80% chance of PONV, respectively. The basic inclusion 
criteria were female gender and nonsmoking status because 
all patients were anticipated to require postoperative opioids. 
The exclusion criteria were severe bowel motility impairment, 
insulin-dependent diabetes mellitus, pregnancy or breast 
feeding, the administration of an antiemetic before surgery, 
systemic treatment with steroids before surgery, a history of 
cardiovascular or respiratory disease, and an impaired renal 
and/or hepatic function. 
    Patients were randomly allocated to either a control group 
(n = 65) or a ramosetron group (n = 65) using a computerized 
generated randomization table. Patients’ characteristics, 
including a history of PONV and/or motion sickness, and 
operative data were similar in both groups (Table 1), as were the 
expected risks for PONV using the Apfel scoring system [13]. 
    The anesthetic regimen was standardized. Anesthesia was 
induced and maintained with propofol (target effect-site con-
centration of 2.5-3.5 μg/ml) and remifentanil (target effect-
site concentration of 2.5-3.5 ng/ml), using a target controlled 
device (Orchestra; Fresenius Kabi, Bad Homburg, Germany), 
and 0.6 mg/kg of rocuronium was administered to facilitate 
tracheal intubation. Mechanically controlled ventilation was 
done using an O2/air mixture (fractional inspired oxygen 
[FiO2] = 0.6) and was adjusted to maintain an end-tidal CO2 
concentration of between 35 and 40 mmHg throughout surgery. 
    20 minutes before the end of surgery, patients were admini-
stered either 2 ml of normal saline (the control group) or 0.3 mg 
of ramosetron in 2 ml (the ramosetron group). Injected drugs 
were prepared in identical syringes by personnel not otherwise 
involved in this study. The intravenous patient-controlled 
analgesia (IV PCA) regimen consisted of 10 μg/kg of fentanyl 
and 3 mg/kg of ketorolac (total volume including saline: 100 
ml) and was programmed to deliver 2 ml/h as a background 
infusion and 0.5 ml on demand (with a 15 minute lockout) 
during the first 48 hours after the end of surgery.
Table 1. Patient Characteristics and Calculated Risks for Post-
operative Nausea and Vomiting 
Group C
(n = 65)
Group R
(n = 65)
Age (yr)
Height (cm)
Weight (kg)
Operation time (hour)
Anesthesia time (hour)
History of PONV 
History of motion sickness 
Apfel score*
    3
    4 
Calculated risk (%)
 47.7 ± 9.8
158.3 ± 5.2
 61.7 ± 9.1
  3.4 ± 0.8
  4.0 ± 0.8
6 (9%)
14 (22%)
47 (72%)
18 (28%)
66%
 46.4 ± 9.2
159.0 ± 5.6
 60.4 ± 8.4
  3.4 ± 0.8
  4.0 ± 0.8
8 (12%)
14 (22%)
46 (71%)
19 (29%)
66%
Values are means ± SDs or the number of patients (percentages). Group 
C: control group, Group R: ramosetron group, PONV: postoperative 
nausea and vomiting. *The presence of 0, 1, 2, 3, or 4 of the risk 
factors (female gender, non-smoking, the use of postoperative 
opioids, and a prior history of motion sickness or PONV) correspond 
to approximately 10, 20, 40, 60, and 80% risks of PONV.156 www.ekja.org
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    The incidence and severity of PONV, pain score, admini-
strations of rescue antiemetics, and the side effects of the 
antiemetics during the first 48 hour period after surgery were 
recorded. These variables were assessed by investigators 
unaware of the group identities, and subdivided into 3 time 
periods: 0 to 6 hours, 6 to 24 hours, and 24 to 48 hours post-
emergence. Nausea was defined as a subjectively unpleasant 
sensation associated with an awareness of the urge to vomit. 
Nausea severities were determined using verbally rated scores, 
where mild was defined as a score of 1-3, moderate as a score 
of 4-6, and severe as a score of 7-10. Vomiting was defined as 
the forceful expulsion of gastric contents from the mouth. Pain 
intensity scores were measured using a verbally rated 11-point 
scale, where 0 = no pain and 10 = worst imaginable pain. The 
satisfaction score was graded on verbal rating scales using an 
11-point scale, with 0 = very unsatisfied to 10 = very satisfied. 
Antiemetic efficacy was assessed by monitoring the incidence 
and severity of nausea and vomiting and by the administrations 
of rescue antiemetic medication. Rescue antiemetic therapy 
(metoclopramide 10 mg IV) was given at the discretion of 
the attending physicians, who were also unaware of the 
group identities, in response to nausea, vomiting, or at the 
patient’s request. Patients were allowed 30 mg IV of ketorolac 
if they complained of pain ≥ 5 on the verbal rating scale. The 
incidences of the most frequently reported side effects of the 
5-HT3 antagonists used in conjunction with the opioid-based 
IV PCA, such as, headache, dizziness, and drowsiness, were 
also assessed [14]. In addition, the duration of the surgeries and 
anesthesia were recorded.
    The study sample size was predetermined by power analysis 
based on the following assumptions: (a) the incidence of 
complete response (no nausea, no retching, no vomiting), 
which was regarded as the primary endpoint, in the control 
group would be 65% (based on a study by Lee et al. [15]); (b) 
an improvement from 65% to 90% was of clinical importance, 
and (c) an α of 0.05 with a power (1-β) of 0.9. This analysis 
showed that 57 patients per group would be required to detect 
a clinically meaningful antiemetic effect. Statistical analyses 
were performed using SPSS ver. 13.0 (SPSS Inc., Chicago, IL). 
All data are expressed as the means ± standard deviations (SDs) 
or as the number of patients and percentages. Group variables 
were compared using the chi-square test, Fisher’s exact test, the 
independent t-test, or the Mann-Whitney U test as appropriate. 
Statistical significance was accepted for P values of < 0.05. 
Results
    The incidences of postoperative nausea, vomiting, and com-
plete response are listed in Table 2. The incidence of complete 
response in the control and the ramosetron groups was 71% 
and 88%, respectively, during the first 6 h (P = 0.029), 85% and 
94% from the next 6 to 24 h (P = 0.155), and 97% and 95% from 
the last 24 to 48 h (P = 1.00). During the first 6 hour period 
after emergence, the incidence of complete response was 
significantly higher, and the severity of nausea and the use of 
rescue antiemetic medication were significantly lower in the 
ramosetron group, but these effects were not observed during 
the other periods. No significant inter-group difference was 
found with respect to vomiting during any of the study periods, 
or with respect to the incidence of side effects (Table 2), and no 
Table 2. Incidences and Severities of Nausea and Vomiting and 
Requirements for Rescue Antiemetic Treatment
Group C
(n = 65)
Group R
(n = 65)
P
0-6 hour
    Complete response
    Nausea
        Mild/moderate/severe
    Vomiting
    Rescue antiemetics
6-24 hour
    Complete response
    Nausea
        Mild/moderate/severe
    Vomiting
    Rescue antiemetics
24-48 hour
    Complete response
    Nausea
        Mild/moderate/severe
    Vomiting
    Rescue antiemetics
Side effects of antiemetics
    Headache
    Dizziness
    Drowsiness 
46 (71%)
19 (29%)
7/7/5
2 (3%)
8 (12%)
55 (85%)
10 (15%)
7/2/1
2 (3%)
1 (2%)
63 (97%)
2 (3%)
2/0/0
0 (0%)
0 (0%)
29 (45%)
13 (20%)
11 (17%)
57 (88%)
8 (12%)
5/3/0
2 (3%)
1 (2%)
61 (94%)
4 (6%)
2/1/1
2 (3%)
1 (2%)
62 (95%)
3 (5%)
1/0/2
0 (0%)
1 (2%)
27 (42%)
11 (17%)
12 (18%)
0.029*
0.029*
0.044*
0.298
0.033*
0.155
0.155
0.331
1.000
1.000
1.000
1.000
0.310
1.000
1.000
0.860
0.822
1.000
Values are the number of patients (percentages). Group C: control 
group, Group R: ramosetron group. *P < 0.05 compared with Group C.
Table 3.  Pain Intensity and Satisfaction Scores and Requirements for 
Analgesic Treatment
Group C
(n = 65)
Group R
(n = 65)
P
Pain score
    0-6 hour
    6-24 hour
    24-48 hour
Satisfaction score 
    0-6 hour
    6-24 hour
    24-48 hour
Analgesic treatment
3.8 ± 2.1
2.7 ± 1.9
1.9 ± 1.8
7.2 ± 1.5
8.1 ± 1.3
8.8 ± 1.0
20 (31%)
3.2 ± 2.1
2.3 ± 1.9
2.0 ± 1.9
7.6 ± 1.6
8.5 ± 1.3
8.9 ± 1.1
18 (28%)
0.064
0.238
0.779
0.072
0.056
0.672
0.847
Values are means ± SDs or the number of patients (percentages). 
Group C: control group, Group R: ramosetron group.157 www.ekja.org
Korean J Anesthesiol Lee, et al.
patient was withdrawn from the study because of an adverse 
event.
    Furthermore, no significant difference in pain or satisfaction 
score or in the use of analgesics was observed between the 
two groups during the study periods (Table 3). Fentanyl 
consumption was 624.2 ± 87.8 μg in the control group versus 
601.7 ± 76.9 μg in the ramosetron group (P = 0.122). Keromine 
consumption was 172.6 ± 23.1 mg in the control group versus 
168.5 ± 21.0 mg in the ramosetron group (P = 0.286). 
Discussion
    Thyroidectomy is associated with a relatively high incidence 
of PONV. PONV can be particularly problematic after thyroidec-
tomy since it can lead to serious complications, such as wound 
dehiscence or airway obstruction by a hematoma caused by 
increased venous pressure. Accordingly, PONV is the anesthetic 
complication of greatest concern for patients and continues to 
be a significant concern for anesthesiologists.
    Ramosetron is a newly developed 5-HT3 receptor antagonist 
with a more potent and longer receptor antagonizing effect 
compared with older 5-HT3 receptor antagonists [16]. In 
addition, the elimination half-life of ramosetron (9 h) is longer 
than that of ondansetron (3.5 h) or granisetron (4.9 h) [17,18]. 
Furthermore, ramosetron has been reported to be an effective 
antiemetic in patients that have undergone various surgeries 
[4,5,9-12]. In the present study, the dose of ramosetron used 
was decided by referring to previous studies by Fujii et al. 
[5,9,10,12], who reported that a minimum of 0.3 mg of ramos-
etron is required to prevent PONV during the first 48 h after 
thyroidectomy with isoflurane anesthesia [5]. 
    A systemic review of 84 randomized, controlled trials that 
compared propofol with inhalational agents showed that the 
preventative effects of propofol on PONV were significant only 
in high-risk patients during early PONV (< 6 h) [19]. Apfel et 
al. [20] concluded, in a randomized controlled study of 1,180 
patients at high-risk of PONV, that the risk factors of late PONV 
(2-24 h) and early PONV (< 2 h) differ. Anesthetic technique 
(inhalation vs. TIVA) was not identified as a risk factor of late 
PONV. White et al. [8] suggested that a longer-acting antiemetic 
might be necessary to reduce late PONV (especially post-
discharge nausea and vomiting) after TIVA. The premise of 
this study was that ramosetron would be more effective on late 
than early PONV in patients after TIVA. However, although 
we found a trend toward a greater complete response in the 
ramosetron group, this was significant only during early PONV 
(< 6 h), which is consistent with the results of Lee et al. on 
the prevention of PONV in patients after propofol based TIVA 
[15]. These workers found that 0.3 mg of IV ramosetron was 
effective at preventing PONV only during the first 1 h after 
surgery in patients undergoing gynecologic laparoscopy [15]. 
In addition, another study showed that 8 mg of ondansetron, 
which possesses shorter action properties than ramosetron, was 
as effective as 0.3 mg of ramosetron at preventing PONV after 
gynecological surgery with sevoflurane anesthesia [21]. Another 
explanation for the effect of ramosetron on late PONV is that the 
incidence of PONV was low due to the preventative effect of the 
propofol. A previous review article showed the late complete 
response in the propofol group was 91.4% [19]. And, in spite of 
the high risk patients, complete response in the control group 
was 97% during the 24 to 48 h postoperative period in this study. 
In these studies, there would not be enough nausea or vomiting 
to allow for the sensitive assay of treatment efficacy due to a 
low incidence of PONV. Moreover, we do not have to consider 
antiemetics when the incidence of PONV without treatment 
was low. Accordingly, the effect of ramosetron and TIVA on late 
PONV in patients continues to be debated.
    IV PCA based on opioids is known to be an effective and 
safe method with a high satisfaction rate for pain control after 
surgery [22]. However, postoperative analgesia with opioids is 
associated with an incidence of PONV in over 30% of patients 
[23,24]. Therefore, when opioid-based IV PCA is planned in 
patients who are at high risk of PONV, appropriate prophylactic 
antiemetic treatment should be considered. The results of 
the present study show that 0.3 mg of ramosetron reduces 
the incidence of nausea in women that have undergone total 
thyroidectomy during the early postoperative period. This result 
concurs with that of a previous study by Choi et al. [25], who 
demonstrated that ramosetron is superior to ondansetron for 
preventing severe nausea and vomiting related to fentanyl-
based IV PCA during the first 24 h after spine surgery. 
    Some investigators have advised against the use of 5-HT3 
receptor antagonists, such as ramosetron, because of the cost 
involved. In Korea, ramosetron (US $55.65 for 0.3 mg) is much 
more expensive than other commonly used antiemetics, such as 
metoclopramide (US $0.48 for 10 mg), which are administered 
as rescue antiemetics. Moreover, although ramosetron is a long 
acting antiemetic agent, it did not reduce late PONV in patients 
on propofol-based TIVA. Therefore, there is an uncertainty 
about the cost effective benefit of ramosetron in patients 
undergoing TIVA. However, the use of traditional antiemetics is 
limited by their side effects, which include sedative, dysphoric, 
and extrapyramidal symptoms. Thus, if patients are prepared to 
pay around US $17-56 for an antiemetic that would completely 
prevent PONV [26-28], anesthesiologists should make an 
informed choice regarding the antiemetic used.
    In conclusion, we found that ramosetron was effective 
at preventing PONV in women that had undergone total 
thyroidectomy with propofol-based TIVA, especially during the 
first 6 h after surgery.158 www.ekja.org
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